Noradrenergic and dopaminergic activity in the hypothalamic paraventricular nucleus after naloxone-induced morphine withdrawal

Neuroendocrinology

Volumn 71, Issue 1, 2000, Pages 60-67

  Fuertes, Gregorio ^a   Laorden, M Luisa ^a   Milańs, M Victoria ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Adrenal steroids; cAMP; Catecholamines; Morphine behaviour; Naloxone; Paraventricular nucleus; Withdrawal syndrome

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CYCLIC AMP; DOPAMINE; NALOXONE; NORADRENALIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG WITHDRAWAL; HYPOPHYSIS ADRENAL SYSTEM; MALE; MORPHINE ADDICTION; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; THALAMUS MIDLINE NUCLEUS;

EID: 0033954309     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054521     Document Type: Article

References (41)

1. Nestler EJ: Molecular mechanism of drug addiction. J Neurosci 1992;12:2439-2450.
2. Nestler EJ, Hope BT, Widnell KL: Drug addiction: A model for molecular basis of neural plasticity. Neuron 1993;11:995-1006.
3. Kooh GF: Drugs of abuse: Anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992;13:177-184.
4. Self DW, Nestler EJ: Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995;18:463-495.
5. Guitart X, Thompson MA, Mirante CK, Greenberg ME, Nestler EJ: Regulation of cyclic AMP response element-binding protein (CREB) phosphorylation by acute and chronic morphine in the tar locus coerulcus. J Neurochem 1992;58:1168-1171.
6. Pechnick RN: Effects of opioids on the hypothalamo-pituitary-adrenal axis. Annu Rev Pharmacol Toxicol 1993;32:353-382.
7. Alcaraz C, Vargas ML, Fuente T, Milańs MV: Chronic naloxone treatment induced supersensitivity to a μ but not to a κ agonist at the hypothalamus-pituitary-adrenocortical axis level. J Pharmacol Exp Ther 1993;266:1602-1606.
8. Gonzálvez ML, Milanés MV, Vargas ML: Effects of acute and chronic administration of μ- and δ-opioid agonists on the hypothalamic-pituitary-adrenocortical (HPA) axis in the rat. Eur J Pharmacol 1991;200:155-158.
9. Martínez JA, Vargas ML, Fuente T, del Rio-Garcia J, Milanés MV: Plasma β-endorphin and cortisol levels in morphine-tolerant rats and in naloxone-induced withdrawal. Eur J Pharmacol 1990;182:117-123.
10. Vargas ML, Martinez-Piñero MG, Milanés MV: Neurochemical activity of noradrenergic neurons and pituitary-adrenal response after naloxone-induced withdrawal: The role of calcium channels. Naunyn-Schmiedeberg's Arch Pharmacol 1997;355:501-506.
11. Suemaru S, Dallman MF, Darlington DN, Cascio CS, Shisako J: Role of α-adrenergic mechanisms in effects of morphine on the hypothalamo-pituitary-adrenocortical and cardiovascular systems in the rat. Neuroendocrinology 1989;49:181-190.
12. Martinez-Piñero MG, Milańs MV, Alcaraz C, Vargas ML: Catecholaminergic mediation of morphine-induced activation of pituitary-adrenocortical axis in the rat: Implication of α- and β-adrenoceptors. Brain Res 1994;668:122-128.
13. Milańs MV, Laorden ML, Chapleur-Chateau M, Burlet A: Alterations in corticotropin-releasing factor and vasopressin content in rat brain during morphine withdrawal. Correlation with hypothalamic noradrencrgic activity and pituitary-adrenal response. J Pharmacol Exp Ther 1998;285:700-706.
14. Milańs MV, Laorden ML, Chapleur-Chateau M, Burlet A: Differential regulation of corticotropin-releasing factor and vasopressin in discrete brain regions after morphine administration: Correlations with hypothalamic noradrenergic activity and pituitary-adrenal response. Naunyn-Schmiedeberg's Arch Pharmacol 1997;356:603-610.
15. Palkovits M: Anatomy of neural pathways affecting CRH secretion. Ann NY Acad Sci 1987; 512:139-148.
16. Cunningham ET, Sawchenko PE: Anatomical specificity of noradrenergic inputs to the paraventricular and supraoptic nuclei of the rat hypothalamus. J Comp Neurol 1988;274:60-76.
17. Owens MJ, Nemeroff CB: Physiology and pharmacology of corticotropin releasing factor. Pharmacol Rev 1991;43:425-473.
18. Plotsky PM, Cunningham ET, Widmaier EP: Catrcholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev 1989;10:437-458.
19. Itoi K, Suda T, Tozawa F, Dobashi I, Ohmori N, Sakai Y, Abe K, Demura H: Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus stimulates corticotropin-releasing factor gene expression in conscious rats. Endocrinology 1994;135:2177-2182.
20. Bugajski J, Gadek-Michalska A, Olowska A, Borycz J, Glód R, Bugajski AJ: Adrenergic regulation of the hypothalamic-pituitary-adrenal axis under basal and social stress conditions. J Physiol Pharmacol 1995;46:297-312.
21. Everitt BJ, Meister B, Höfelt T: The organization of monoaminergic neurons in the hypothalamus in relation to neuroendocrine integration; in Nemeroff CB (ed): Neuroendocrinology. Boca Raton, CRC Press, 1992, pp87-127.
22. Torres G, Horowitz JM: Individual and combined effects of ethanol and cocaine on intracellular signals and gene expression. Prog Neuropsychopharmacol Biol Psychiatry 1996;20: 561-596.
23. Gonzálvez ML, Milanés MV, Martínez-Piñero MG, Marín MT, Vargas ML: Effects of intracerebroventricular clonidine on the hypothalamic noradrenaline and plasma corticosterone levels of opiate naïve rats and after naloxone-induced withdrawal. Brain Res 1994;647:199-203.
24. Couceyro P, Douglass J: Precipitated morphine withdrawal stimulates multiple activator protein-I signaling pathways in rat brain. Mol Pharmacol 1995;47:29-39.
25. Berhow MT, Russel DS, Terwilliger RZ, Beitner-Johnson D, Self DW, Lindsay RM, Nestler EJ: Influence of neurotrophic factors on morphine- and cocaine-induced biochemical changes in the mesolimbie dopamine system. Neuroscience 1995;68:969-979.
26. Yokoe T, Audhya T, Brown C, Hutchinson B, Passarelli J, Hollander CS: Corticotropin-releasing factor levels in the peripheral plasma and hypothalamus of the rat vary in parallel with changes in the pituitary-adrenal axis. Endocrinology 1988;123:1348-1354.
27. Palkovits M: Isolated removal of hypothalamic or other brain nuclei of the rat. Brain Res 1973; 59;449-450.
28. Palkovits M. Brownstein MJ: Maps and guide to microdissection of the rat brain. New York, Elsevier, 1988.
29. Artigas F, Sarrias MJ, Adell A, Gelpi E: Quantitation of total MHPG in the rat brain using a nonenzymatic hydrolysis procedure. Effects of drugs. Life Sci 1986;39:1571-1578.
30. Lookingland KJ, Ireland LM, Gunnel JW, Manzanares J, Tian Y, Moore KE: 3-Methoxy-4-hydroxyphenylethyleneglycol concentrations in discrete hypothalamic nuclei reflect the activity of noradrenergic neurons. Brain Res 1991;559:82-88.
31. Ignar DM, Kuhn CM: Effects of specific μ and κ opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J Pharmacol Exp Ther 1990;255:1287-1295.
32. De Vries TJ, Tjon Tien Ril GHK, van der Laan JW, Mulder AH, Schoffelmeer ANM: Chronic exposure to morphine and naltrexone induces changes in catecholaminergic neurotransmission in rat brain without altering μ-opioid receptor sensitivity. Life Sci 1993;52:1685-1693.
33. Manzanares J, Lookingland KJ, Moore KE: κ-opioid receptor-mediated regulation of α-metanocyte stimulating hormone secretion and tuberohypophysial dopaminergic neuronal activity. Neuroendocrinology 1990;52:200-205.
34. Lightman SL, Young WS: Corticotropin-releasing factor, vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the rat. J Physiol 1988;403:511-523.
35. Harbuz M, Russell JA, Sumnier BEH, Kawata M, Lightman SL: Rapid changes in the content of proenkephalin A and corticotrophin releasing hormone mRNAs in the paraventricular nucleus during morphine withdrawal in urethane-anesthetized rats. Mol Brain Res 1991;9: 285-291.
36. Petrusz P, Merchenthaler I: The corticotropin-releasing factor system; in Nemeroff CB (ed): Neuroendocrinology. Boca Raton, CRC Press, 1992, pp 129-183.
37. Hasting JA, Pavia JM, Morris MJ: Altered in vivo catecholamine release in the hypothalamic paraventricular nucleus of the aged rat. Naunyn-Schmiedeberg's Arch Pharmacol 1996; 353:161-167.
38. Borowsky B, Kuhn CM: GBR12909 stimulates hypothalamo-pituitary-adrenal activity by inhibition of uptake at hypothalamic dopaminergic neurons. Brain Res 1993;613:251-258.
39. Torres G, Horowitz JM, Lee S, Rivier C: Cocacthylcne stimulates the secretion of ACTH and corticosterone and the transcriptional activation of hypothalamic NGFI-B. Mol Brain Res 1996;43:225-232.
40. Valverde O, Tzavara F, Hanoune J, Roques BP, Maldonado R: Protein kinases in the rat nucleus accumbens are involved in the aversive component of opiate withdrawal. Eur J Neurosci 1997;8:2671-2678.
41. Sheu MJ, Sribanditmongkol P, Santosa DN, Tejwani GA: Inhibition of morphine tolerance and dependence by diazepam and its relation to cyclic AMP levels in discrete rat brain regions and spinal cord. Brain Res 1995;675:31-37.